Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Expression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells


ABSTRACT: Prostate cancer C4-2B cells were cultured in enzalutamide in a dose-escalation manner. After sixty passages cells were resistant to enzalutamide, with a specific sets of genes been deregulated. We performed global gene expression analysis by cDNA microarrays to identify genes responsible for enzalutamide resistance in C4-2B-MDVR cells. Enzalutamide resistant C4-2B-MDVR cells were selected from C4-2B cells during long time enzalutamide treatment. Genes responsible for enzalutamide resistance were identified using C4-2B vs. C4-2B-MDVR RNA extraction and hybridization on Affymetrix microarrays.

ORGANISM(S): Homo sapiens

SUBMITTER: allen Gao 

PROVIDER: E-GEOD-64143 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.

Liu Chengfei C   Lou Wei W   Zhu Yezi Y   Yang Joy C JC   Nadiminty Nagalakshmi N   Gaikwad Nilesh W NW   Evans Christopher P CP   Gao Allen C AC  

Cancer research 20150203 7


The introduction of enzalutamide and abiraterone has led to improvement in the treatment of metastatic castration-resistant prostate cancer. However, acquired resistance to enzalutamide and abiraterone therapies frequently develops within a short period in many patients. In the present study, we developed enzalutamide-resistant prostate cancer cells in an effort to understand the mechanisms of resistance. Global gene-expression analysis showed that the steroid biosynthesis pathway is activated i  ...[more]

Similar Datasets

2015-04-09 | GSE64143 | GEO
2020-10-20 | GSE159548 | GEO
2020-02-01 | GSE110802 | GEO
2022-11-02 | GSE216777 | GEO
2013-08-01 | E-GEOD-47040 | biostudies-arrayexpress
| PRJNA531908 | ENA
2019-09-29 | GSE129596 | GEO
| PRJNA669681 | ENA
2022-12-01 | GSE189966 | GEO
| PRJNA895368 | ENA